2022-RA-1436-ESGO Pelvic exenteration – boon or a bane ? Analysis from tertiary care cancercentre. (20th October 2022)

• Record Type: Journal Article
• Authors: Mishra, Ashutosh; Ray, Mukurdipi; Deo, SVS; Premanand, N; Surya Talluri, Sri Harsha Vardhan
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A59
• Page End: A60
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.129
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Pelvic exenteration is a complex procedure and usually the only viable salvage option in recurrent cervical and rectal cancer. However, postoperative morbidity is deemed unfavourable by many groups. Our aim of the study is to analyse the patient profile and perioperative outcomes with survival data in our cohort. Methodology: An analysis of prospectively maintained computerized database was performed including patients undergoing pelvic exenteration from 2012 to 2021 for surgical and survival outcomes. Results: A total of 65 patients were included. Mean age of the patients was 46.17 (18–70 years). Predominant primary sites were rectum, ovary and cervix. All were curative intent resections. Majority of patients underwent supra-levator posterior exenteration.Mean duration of surgery was 342.30 min (150–600 min). Mean blood loss was 614.89 ml (100 ml to 2500 ml). Length of hospital stay was on average 11.16 days (5–45 days). R0, R1 resection rates were 97.5% and 2.5% respectively. In-hospital mortality was 3.6%. Urinary leak rates (5.6%), GI anastomotic leak (7.27%), enteric fistula (9.09%).Follow up data was available for 38 patients, 14 expired due to disease (26.9%), with median time to death from surgery of 14.3 months (2.3–57.53 months). Overall, 58.3% of the patients were alive at the end of 3 years (with available follow up data). Conclusion: Long term outcomes are favourable with pelvic exenteration in select subset of patients with acceptable morbidity.